What is MGNX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MGNX?

P/E (TTM) is n/a and 52-week range is $1.29 to $5.08 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MGNX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MGNX?

The company profile lists revenue (TTM) near $168M, net income (TTM) near $-1.46B, EPS (TTM) near $-0.23 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MacroGenics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rockville, Maryland, US, 63.6M shares outstanding, ISIN US5560991094 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

MacroGenics Inc

$MGNX

Health Care · Biotechnology

IR Run Scenarios

$3.74

+5.35%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 293 full-time employees. The company went IPO on 2013-10-10. The firm generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Employees

293

Website

www.macrogenics.com/

IPO

2013-10-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)